The IGFBP-2 level was positively correlated with constitutional (r = 0.260, p = 0.038), cutaneous (r = 0.257, p = 0.040), gastrointestinal (r = 0.330, p = 0.008), muscle (r = 0.336, p = 0.007), and global (r = 0.380, p = 0.002) disease activity in all DM patients. This evidence concerns the gene IGFBP2 and dermatomyositis.